Sesame Care vs 1st Optimal
Two GLP-1 desks, one scoreboard. We put Sesame Care and 1st Optimal head-to-head on the published Brief Score — the same six factors, scored the same way.
Sesame Care
The verdict
Sesame Care takes this head-to-head.
Sesame Care scores 87 to 46 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.
That doesn't make 1st Optimal a bad call — it's best for patients wanting glp-1 therapy within a lab-driven functional-medicine program. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Sesame Care | 1st Optimal | |
|---|---|---|
| Brief Score | 87/100 (B+) | 46/100 (C) |
| Semaglutide | From $149/mo (brand Wegovy pill) | Not disclosed |
| Tirzepatide | Brand Zepbound (price varies) | Not disclosed |
| Coverage | Nationwide marketplace | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.
1st Optimal: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.